Renessans Helps in Early Clearance of SARS-CoV-2: Activity of the Iodine Complex in

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Sep 23

PMID 36143459

Authors

Muhammad Nawaz

Muhammad Adnan Ashraf

Muhammad Asad Ali

Muhammad Zubair Shabbir

Muhammad Abu Bakr Shabbir

Imran Altaf

Sohail Raza

Saira Rafique

Sohail Hassan

Nageen Sardar

Adnan Mehmood

Muhammad Waqar Aziz

Sehar Fazal

Muhammad Tahir Khan

Hafiz Muhammad Moavia Atique

Ali Asif

Zia Ullah

Mubashir Iqbal

Talha Imtiaz

Muhammad Anwar

Nadia Mukhtar

Tahir Yaqub

Affiliations

Soon will be listed here.

Abstract

Iodine complexes have known antimicrobial properties along with reported antiviral activity for several viruses. Renessans is one such product with iodine complexes and ascorbic acid. The present study was designed to determine its efficacy for SARS-CoV-2 in . were assigned to: A) prophylactic group (n = 3), (B) treatment group (n = 3), (C) infection control group (n = 4), and (D) negative control group (n = 4). Groups A, B, and C were challenged with 2 × 10 TCID of SARS-CoV-2. The prophylactic group (A) was administered Renessans from 5 days before infection till 8 days postinfection (DPI). The treatment group (B) was administered Renessans from 3 till 8 DPI. Group C was administered water-insoluble fractions only. Nasal swabs from all monkeys of groups A, B, and C remained positive for SARS-CoV-2 till 2 and 7 DPI, while the swabs became negative for groups A and B at 14 DPI. Likewise, fecal matter of monkeys in group A returned negative results during the experiment, while that of group B had significantly decreased viral load (10 genome copies/mL) compared to group C (10 genome copies/mL). Hence, it is concluded that Renessans has SARS-CoV-2 activity and may result in early clearance of SARS-CoV-2.

Citing Articles

Patterns of Dietary Supplement Use during the COVID-19 Pandemic in Poland: Focus on Vitamin D and Magnesium.

Grosman-Dziewiszek P, Jeskowiak-Kossakowska I, Szelag A, Wiatrak B Nutrients. 2024; 16(19).

PMID: 39408194 PMC: 11478616. DOI: 10.3390/nu16193225.

COVID-19 Prevention and Treatment.

De Francia S, Chiara F, Allegra S Life (Basel). 2023; 13(3).

PMID: 36983989 PMC: 10059649. DOI: 10.3390/life13030834.

References

Boszormenyi K, Stammes M, Fagrouch Z, Kiemenyi-Kayere G, Niphuis H, Mortier D . The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues. Viruses. 2021; 13(8). PMC: 8402919. DOI: 10.3390/v13081673. View

Pang W, Chehaitli H, Hurd T . Impact of asymptomatic COVID-19 carriers on pandemic policy outcomes. Infect Dis Model. 2021; 7(1):16-29. PMC: 8603921. DOI: 10.1016/j.idm.2021.11.003. View

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

Hamuy R, Berman B . Treatment of Herpes simplex virus infections with topical antiviral agents. Eur J Dermatol. 1998; 8(5):310-9. View

Hadj Hassine I . Covid-19 vaccines and variants of concern: A review. Rev Med Virol. 2021; 32(4):e2313. PMC: 8646685. DOI: 10.1002/rmv.2313. View

Elzein R, Abdel-Sater F, Fakhreddine S, Abi Hanna P, Feghali R, Hamad H . In vivo evaluation of the virucidal efficacy of chlorhexidine and povidone-iodine mouthwashes against salivary SARS-CoV-2. A randomized-controlled clinical trial. J Evid Based Dent Pract. 2021; 21(3):101584. PMC: 8080510. DOI: 10.1016/j.jebdp.2021.101584. View

Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H . Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 2021; 12(1):2506. PMC: 8096808. DOI: 10.1038/s41467-021-22781-1. View

Eggers M, Eickmann M, Zorn J . Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA). Infect Dis Ther. 2015; 4(4):491-501. PMC: 4675768. DOI: 10.1007/s40121-015-0091-9. View

Pelletier J, Tessema B, Frank S, Westover J, Brown S, Capriotti J . Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). Ear Nose Throat J. 2020; 100(2_suppl):192S-196S. DOI: 10.1177/0145561320957237. View

10.

Zheng H, Li H, Guo L, Liang Y, Li J, Wang X . Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression. PLoS Pathog. 2020; 16(11):e1008949. PMC: 7660522. DOI: 10.1371/journal.ppat.1008949. View

11.

Zhao X, Chen D, Szabla R, Zheng M, Li G, Du P . Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. J Virol. 2020; 94(18). PMC: 7459545. DOI: 10.1128/JVI.00940-20. View

12.

Gottardi W . Iodine and disinfection: theoretical study on mode of action, efficiency, stability, and analytical aspects in the aqueous system. Arch Pharm (Weinheim). 1999; 332(5):151-7. DOI: 10.1002/(sici)1521-4184(19995)332:5<151::aid-ardp151>3.0.co;2-e. View

13.

Song T, Han J, Yang X, Li M, Zheng Y . Tissue distribution of SARS-CoV-2 in non-human primates after combined intratracheal and intranasal inoculation. Sci China Life Sci. 2021; 64(10):1792-1794. PMC: 7882853. DOI: 10.1007/s11427-020-1877-4. View

14.

Altaf I, Nadeem M, Hussain N, Nawaz M, Raza S, Shabbir M . An in vitro antiviral activity of iodine complexes against SARS-CoV-2. Arch Microbiol. 2021; 203(7):4743-4749. PMC: 8208607. DOI: 10.1007/s00203-021-02430-3. View

15.

Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z . ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020; 18(9):2128-2130.e2. PMC: 7194639. DOI: 10.1016/j.cgh.2020.04.040. View

16.

Dhawan M, Emran T, Choudhary O . Implications of COVID-19 vaccine boosters amid the emergence of novel variants of SARS-CoV-2. Ann Med Surg (Lond). 2022; 77:103612. PMC: 9001012. DOI: 10.1016/j.amsu.2022.103612. View

17.

Pan L, Luo R, Wang T, Qi M, Wang B, Sun M . Efficient inactivation of African swine fever virus by a highly complexed iodine. Vet Microbiol. 2021; 263:109245. DOI: 10.1016/j.vetmic.2021.109245. View

18.

Anderson D, Sivalingam V, Kang A, Ananthanarayanan A, Arumugam H, Jenkins T . Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease. Infect Dis Ther. 2020; 9(3):669-675. PMC: 7341475. DOI: 10.1007/s40121-020-00316-3. View

19.

Martinez Lamas L, Diz Dios P, Perez Rodriguez M, Perez V, Cabrera Alvargonzalez J, Lopez Dominguez A . Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests. Oral Dis. 2020; 28 Suppl 1:908-911. PMC: 7362147. DOI: 10.1111/odi.13526. View

20.

Lake M . What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020; 20(2):124-127. PMC: 7081812. DOI: 10.7861/clinmed.2019-coron. View